Olaparib

Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Though the combination of cediranib and olaparib did not beat out platinum-based chemotherapy, it was more effective in patients with germline BRCA mutations, according to Ursula A. Matulonis, MD, of Dana Farber Cancer Institute.

In this video, Sara M. Tolaney, MD, MPH, breast medical oncologist at Dana Farber Cancer Institute, shared her perspectives on data from the TBCRC 048 trial presented during the ASCO20 Virtual Scientific Program.

In this video, Halle Moore, MD, director of Breast Medical Oncology in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about presentations in breast cancer at the virtual ASCO Annual Meeting.

The FDA approved olaparib for treatment of certain men with metastatic castration-resistant prostate cancer.

Maintenance therapy with olaparib extended OS compared with placebo among women with platinum-sensitive, BRCA-mutated relapsed ovarian cancer, according to the final analysis of the randomized phase 3 SOLO-2 study scheduled for presentation during the ASCO20 Virtual Scientific Program.

The FDA expanded the approval of olaparib to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

Durvalumab and olaparib in combination with paclitaxel significantly improved pathologic complete response compared with chemotherapy alone among women with stage II or stage III high-risk, HER2-negative breast cancer, according to results of the randomized phase 2 I-SPY 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

The combination of cediranib and olaparib failed to extend PFS compared with platinum-based chemotherapy for a subset of women with ovarian cancer, according to topline results of a randomized phase 3 trial.

The FDA granted priority review to olaparib for the treatment of men with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations who progressed on treatment with a new hormonal agent, according to a press release from the agent’s manufacturers.